在成功再灌输的缺血性中风患者中,大脑氧气代谢率的纵向演变
Victoria Mercy Kataike1, Patricia M Desmond1, Christopher Steward1
1From the Department of Radiology (V.M.K., P.M.D., C.S., V.V.), and Department of Medicine at the Royal Melbourne Hospital (B.C.V.C., F.N.), The University of Melbourne, Parkville, Victoria, Australia; Department of Medical Imaging (P.M.D., C.S., V.V.), and Department of Neurology (B.C.V.C., F.N.), The Royal Melbourne Hospital, Parkville, Victoria, Australia.
AJNR. American journal of neuroradiology
|January 19, 2026
概括
在中风中心脏病发作中的大脑代谢在成功的再注射治疗后急剧升高,然后随着时间的推移而下降. 更好的功能结果与中风后大脑新陈代谢的改善相关.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 脑卒中研究 脑卒中研究
背景情况:
- 大脑代谢氧率 (CMRO2) 是大脑组织代谢和功能的关键指标.
- 对于缺血性中风患者来说,了解心脏病发作代谢中的反输后变化至关重要.
- 在成功转流性心脏病发作中的长度CMRO2变化仍未得到充分研究.
研究的目的:
- 在成功的内血管血栓切除术 (EVT) 后,检查心脏病发作组织内CMRO2的纵向变化.
- 为了研究CMRO2水平与缺血性中风患者的功能结果之间的关系.
主要方法:
- 51名成功接受EVT的缺血性中风患者被纳入了前性多中心研究.
- 用MRI衍生的CBF和OEF图来计算在EVT后的三个时间点上的CMRO2图.
- 基于mRS分数,分析了相对CMRO2 (心脏病发作与逆侧) 并根据残疾和非残疾患者组进行了比较.
主要成果:
- 相对CMRO2从EVT后24-72小时显著下降到3个月 (p < 0.001).
- 在大多数时间点,非残疾患者的相对CMRO2显著高于残疾患者.
- 这两组在3个月的时间内,相对CMRO2呈现出显著的纵向下降.
结论:
- 在中风中心脏病发作中的相对大脑代谢在血栓切除术后急剧升高,并随着时间的推移而稳定.
- 在具有良好的和差的功能结果的患者之间存在大脑新陈代谢的持续差异.
- CMRO2监测可以提供关于中风恢复和治疗疗效的见解.
更多相关视频
相关概念视频
Metabolic Rate
1.2K
The human body is a powerhouse of energy, with every cell performing numerous functions that require energy. This energy production and consumption is measured by the metabolic rate, which quantifies the total heat generated by all the body's chemical reactions and mechanical work. This measurement helps to determine the rate of kilocalorie (kcal) consumption needed to fuel all ongoing activities.
The Basal Metabolic Rate (BMR) measures the energy expended at rest.
Several factors influence...
The Basal Metabolic Rate (BMR) measures the energy expended at rest.
Several factors influence...
1.2K
The Evidence for Evolution
47.7K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
47.7K
Longitudinal Research
13.1K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.1K
Convergent Evolution
31.4K
Evolution shapes the features of organisms over time, ensuring that they are suited for the environments in which they live. Sometimes, selection pressure leads to the rise of similar but unrelated adaptations in organisms with no recent common ancestors, a process known as convergent evolution.
31.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
196
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
196
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
198
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
198


